华蟾素联合顺铂治疗恶性胸腔积液疗效的文献研究

Meta-analysis of Cinobufacini combined with Cisplatin in the Treatment of Malignant Pleural Effusion

目的:观察华蟾素联合顺铂治疗恶性胸腔积液的临床疗效。方法:基于循证医学评价方法,收集华蟾素联合顺铂治疗恶性胸腔积液的随机对照试验(RCTs),采用Rev Man 5.0软件进行Meta分析。结果:共纳入5篇随机对照研究,共373例病例。与单纯顺铂治疗恶性胸腔积液比较,联合华蟾素明显增加恶性胸腔积液治疗效果,提高患者的生活质量,降低骨髓抑制副反应的发生率,但两组胃肠道毒副作用发生率无统计学差异。结论:华蟾素能提高恶性胸腔积液患者的治疗效果,改善生活质量,并降低顺铂化疗药物的毒副作用,值得临床借鉴。

Objective To assess the clinical efficacy and safety of Cinobufacini combined with Cisplatin for malignant pleural effusion（ MPE）,and to provide evidence- based reference for clinica1 use. Methods A comprehensive search strategy was designed to identify all randomized controlled trials（ RCTs） comparing Cinobufacini plus Cisplatin chemotherapy with Cisplatin chemotherapy alone MPE by searching database. Rev Man 5. 0 software was used for statistical analysis. Results Totally 5 RCTs involving 373 patients were included. The Meta- analysis showed that compared with the pure application of Cisplatin therapy,the combination of Cinobufacini and therapy can enhance the near- term curative effect,improve the quality of life and reduce the suppression of bone marrow,and have no significant differences in reducing the gastrointestinal reactions. Conclusion The current evidence indicates that Cinobufacini can enhance the therapeutic effect on MPE patients,improve the quality of life and reduce adverse effect of pure application of Cisplatin therapy and thus it is worth referring in clinic.